Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3507779 | 0.93 | MAOB (0.54) | MAOBMAPTHTTL3MBTL1MTNR1A | |
| SCHEMBL3761826 | 0.93 | MAOB (0.54) | MAOBMAPTHTTL3MBTL1MTNR1A | |
| SCHEMBL3516327 | 0.86 | MAOB (0.52) | MAOBMAPTHTTL3MBTL1 | |
| SCHEMBL3514027 | 0.86 | MAOB (0.52) | MAOBMAPTHTTL3MBTL1 | |
| SCHEMBL3506523 | 0.83 | MAOB (0.48) | MAOBMAPTHTTL3MBTL1FFAR1 | |
| SCHEMBL7378184 | 0.76 | MAPT (0.58) | MAOBMAPTHTTL3MBTL1FFAR1 | |
| SCHEMBL3691721 | 0.68 | MAOB (0.54) | MAOBMAPTHTTL3MBTL1 | |
| SCHEMBL4709035 | 0.66 | MAOB (0.77) | MAOBMAPTHTTL3MBTL1FFAR1 | |
| SCHEMBL22386761 | 0.65 | MAOB (0.75) | MAOBMAPTHTTL3MBTL1FFAR1 | |
| SCHEMBL7379853 | 0.65 | MTNR1A (0.50) | MAOBMTNR1AFFAR1FFAR4PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5380755-A | Monoamine oxidase inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-01-10 | — | — | US | claimed |
| US-20100247543-A1 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| EP-2195029-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | Oryzon Genomics SA (ES) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009027349-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS SA (ES) | 2009-03-05 | — | — | WO | disclosed |
| US-5380755-A | Monoamine oxidase inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-01-10 | — | — | US | disclosed |